CORT — CORCEPT THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1088856 ·
Last close
$116.10
Market Cap
$12.55B
52W High
$126.38
52W Low
$28.66
ADV30
1,421,517
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 256,147,000 | 252,086,000 | 41,300,000 | 42,987,000 | 888,702,000 | 111,039,000 | 182,926,000 |
| Mar 2026 | 164,903,000 | 162,020,000 | -49,601,000 | -31,761,000 | 814,881,000 | 108,738,000 | 176,894,000 |
| Dec 2025 | 202,125,000 | 199,580,000 | 4,487,000 | 24,288,000 | 836,651,000 | 120,495,000 | 188,846,000 |
| Sep 2025 | 207,638,000 | 203,042,000 | 10,219,000 | 19,668,000 | 823,607,000 | 125,138,000 | 191,705,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$109,700,000
Investing CF
$-21,898,000
Financing CF
$-78,906,000
CapEx
$-2,836,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.42
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$654,613,000
Inventory
$13,185,000
Receivables
$76,920,000
ST Investments
$197,158,000
EBIT TTM
$6,405,000
Pretax Income TTM
$26,369,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$830,812,992
EBITDA
$8,084,000
Free Cash Flow
$77,395,128
Enterprise Value
$11,893,642,240
Total Cash
$308,196,992
Total Debt
$9,421,000
Shares Out
108,098,397
Trailing EPS
$0.45
Book Value
$6.54
ROE
8.2%
ROA
0.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 761,407,000 | 44,797,000 | 99,652,000 | 836,651,000 | 188,846,000 | 647,805,000 | 141,996,000 |
| Dec 2024 | 675,040,000 | 136,951,000 | 141,209,000 | 840,553,000 | 160,964,000 | 679,589,000 | 198,295,000 |
| Dec 2023 | 482,375,000 | 107,282,000 | 106,140,000 | 621,517,000 | 114,812,000 | 506,705,000 | 126,681,000 |
| Dec 2022 | 401,858,000 | 112,634,000 | 101,418,000 | 583,430,000 | 81,588,000 | 501,842,000 | 120,323,000 |
TTM Snapshot
Revenues TTM
$10,102,000
NetIncome TTM
$-4,830,000
OpCashFlow TTM
$0
Assets (Latest)
$51,902,000
Forward EPS
$4.40
Max Pain — expiry 2027-01-15
max pain strike: $95.00 · spot: $116.73 · call oi: 5,608 · put oi: 4,152
Expected Move to 2027-01-15:
±$34.30
(29.38%) —
implied range
$82.43 –
$151.03
· ATM straddle on $115.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | $12.45B | $15.61 | — |
| BBIO | BridgeBio Pharma, Inc. | $12.82B | $65.57 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $11.93B | $516.56 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.66B | $60.26 | — |
| ELAN | Elanco Animal Health Inc | $11.14B | $22.31 | — |
News headlines (Yahoo Finance, 1h cache)
Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)
2026-09-25 15:57 · Yahoo
Corcept Announces Planned Leadership Transition
2026-09-23 12:00 · Yahoo
Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus
2026-09-22 23:23 · Yahoo
Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle
2026-09-22 04:59 · Yahoo
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
2026-09-16 14:44 · Yahoo
2 Healthcare Stocks to Research Further and 1 We Find Risky
2026-09-16 07:00 · Yahoo
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
2026-08-28 15:30 · Yahoo
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
2026-08-20 17:15 · Yahoo
Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales
2026-08-07 22:11 · Yahoo
Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation
2026-08-05 14:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.